Chapters
- 00:00 Introduction - Michael Akoh, CEO
- 00:17:38 Market Opportunity - Steve Dey, Director of Product management and Marketing
- 00:36:26 Growth Strategy - Steve Dey, Director of Product management and Marketing
- 01:02:57 Commercial Engine - Paul Blackburn, CCO
- 01:22:36 Enhanced Purification of Lentiviral Vectors using M-SAN- Lee Davies, Oxford Biomedica
- 01:54:04 Clinical Metagenomics for Rapid Detection of Infections and Antimicrobial Resistance - Rafi Ahmed, University of Inland Norway
- 02:22:18 Financial Profile - Børge Sørvoll, CFO
- 02:31:21 Summary & Outlook - Michael Akoh, CEO
Overview
Discover how ArcticZymes plans to drive the next phase of its commercial evolution by scaling and diversifying its enzyme platform across high-growth biomanufacturing and molecular tools markets.
In this Capital Markets Day session, ArcticZymes’ leadership team outlines the company’s strategy to accelerate innovation, strengthen the product pipeline, and expand adoption across advanced therapies, viral vector manufacturing, RNA workflows, and metagenomics.
The presentation also explores key market drivers, ArcticZymes’ differentiated technology platform, and the customer economics behind enzyme performance in modern bioprocessing and molecular workflows.
Customer speakers share real-world insights into the impact of ArcticZymes enzymes in their processes.
Topics covered include:
- Structural market drivers in advanced therapies, viral vectors, RNA workflows and metagenomics
- ArcticZymes’ differentiated positioning and customer economics
- The strategy to accelerate innovation and strengthen the product pipeline
- Commercial traction and customer adoption dynamics
- The company’s growth ambition supported by organic expansion and selective value-accretive M&A
- Customer presentations detailing the real world impact achieved through using ArcticZyme products
The objective of the day is to provide greater transparency into the company’s growth logic, scalability and long-term value creation potential.
Presentations will be delivered by:
- Michael Akoh, CEO
- Paul Blackburn, CCO
- Børge Sørvoll, CFO
- Steve Dey, Director of Product Management & Marketing
In addition, we will hear directly from customer representatives who will highlight the value generated by adopting ArcticZymes products in their processes. Rafi Ahmad, University of Southampton / University of Inland Norway, will discuss the role of ArcticZymes’ enzymes in his metagenomics workflows and Lee Davies, Oxford Biomedica, who will describe the significant impact of switching to salt active nucleases in viral vector manufacture.
For further information, please contact:
Børge Sørvoll
CFO
ir@arcticzymes.com
+47 952 90 187
